World's first MRIdian center at Barnes-Jewish
Hospital continues to lead the way for advanced precision cancer
therapy with MRI-guided radiation
DENVER, March 2,
2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY)
announced today that the clinical team at Siteman Cancer Center at
Barnes-Jewish Hospital and Washington
University School of Medicine in St. Louis has treated its 2,000th patient
using the MRIdian, MRI-guided radiation therapy system. Patients
treated at Siteman Cancer Center benefit from MRIdian's diagnostic
quality MR visualization on-table adaptive radiotherapy, real-time
tissue tracking, and automated beam control. In January 2014, Siteman Cancer Center became the
first to treat patients using the world's first MRI-guided
radiation therapy system – MRIdian by ViewRay. The clinical team at
Washington University has been a leader
in publishing clinical evidence related to treating various
cancers, including pancreas, prostate, lung, liver, breast, and
oligometastatic cancers.
The Siteman Cancer Center team has generated foundational
peer-reviewed clinical evidence for MRIdian MRI-guided radiation
therapy SBRT (stereotactic body radiotherapy). The body of clinical
evidence includes early studies demonstrating that pancreatic
cancer patients treated with ablative doses contribute to extended
survival; feasibility of on-table adaptive MRIdian SMART
(stereotactic MRI-guided adaptive radiotherapy) for unresectable
primary or oligometastatic malignancies in the abdomen and central
thorax. The team led the way in publishing clinical studies
demonstrating the use of MRI-guided SBRT to treat liver tumors and
has one of the largest volumes of patients. This clinical team was
the first to publish prospective clinical trial data in pancreatic
cancer patients and has treated the largest volume of breast cancer
patients with MRIdian SMART, highlighting the effective use of
short-course (single fraction) treatment.
"As we commemorate our tenth year treating with MRIdian, we
continue to see the data indicating the benefits of MRI-guided
radiation therapy for our patients. MR guidance and adaptive
radiation therapy enable highly therapeutic cancer treatments while
minimizing side effects, improving quality of life, and potentially
even improving survival," said Hyun
Kim, M.D., Associate Professor of Radiation Oncology and MR
Clinical Service Chief at Siteman Cancer Center and Washington University School of Medicine. "MRIdian
has demonstrated in actual patient treatment data the importance of
MRI guidance with adaptive therapy to address anatomical and tumor
changes, real-time soft tissue tracking, and automated beam
control. We treat more than 270 patients per year and are pleased
that we were able to offer this advanced treatment modality to more
than 2,000 patients over the years."
"We are excited to celebrate this key milestone after a decade
of productive partnership with ViewRay. The ability to deliver
on-table adaptive therapy with MRIdian has allowed us to deliver
innovative cancer care to our patients to directly address the
inevitable changes and movement that can take place inside the
body," said Geoffrey Hugo, Ph.D.,
Professor of Radiation Oncology and Director of Medical
Physics, at Siteman Cancer Center and Washington University School of Medicine. "This has
brought us greater precision and control in our radiation delivery
and truly changed how we treat our patients."
The MRIdian system provides oncologists with outstanding
anatomical visualization through diagnostic-quality MR images and
the ability to adapt a radiation therapy plan to the targeted
cancer with the patient on the table. This combination allows
physicians to define tight treatment margins to avoid unnecessary
radiation exposure of vulnerable organs-at-risk and healthy tissue
and allows the delivery of ablative radiation doses in five or
fewer treatment sessions without relying on implanted markers.
MRIdian enables automatic gating of the radiation beam if the
target moves outside the user-defined margins by providing
continuous real-time tracking of the target and organs at risk.
This allows for delivering the prescribed dose to the target while
sparing surrounding healthy tissue and critical structures. This
results in minimizing toxicities typically associated with
conventional radiation therapy.
To date, over 29,000 patients have been treated with MRIdian.
Currently, 57 MRIdian systems are installed at hospitals around the
world, where they are used to treat a wide variety of solid tumors
and are the focus of numerous ongoing research efforts. MRIdian has
been the subject of hundreds of peer-reviewed publications,
scientific meeting abstracts, and presentations. For a list of
treatment centers, please visit:
https://viewray.com/find-mridian-mri-guided-radiation-therapy/
Disclaimer:
Nothing in this material is intended to provide specific medical
advice or to take the place of written law or regulations.
Safety Statement
The MRIdian Linac System is not
appropriate for all patients, including those who are not
candidates for magnetic resonance imaging. Radiation treatments may
cause side effects that can vary depending on the part of the body
being treated. The most frequent ones are typically temporary and
may include, but are not limited to, irritation to the respiratory,
digestive, urinary, or reproductive systems; fatigue; nausea; skin
irritation; and hair loss. In some patients, side effects can be
severe. Treatment sessions may vary in complexity and duration.
Radiation treatment is not appropriate for all cancers. You should
discuss the potential for side effects and their severity as well
as the benefits of radiation and magnetic resonance imaging with
your doctor to make sure radiation treatment is right for you.
About ViewRay
ViewRay, Inc. (Nasdaq: VRAY) designs, manufactures and markets the
MRIdian® MRI-Guided Radiation Therapy System. MRIdian is built upon
a proprietary high-definition MR imaging system designed from the
ground up to address the unique challenges and clinical workflow
for advanced radiation oncology. Unlike MR systems used in
diagnostic radiology, MRIdian's high-definition MR was
purpose-built to address specific challenges, including beam
distortion, skin toxicity, and other concerns that potentially may
arise when high magnetic fields interact with radiation beams.
ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of Section 27A of the Private Securities Litigation Reform
Act. Statements in this press release that are not purely
historical are forward-looking statements. Such forward-looking
statements include, among other things, ViewRay's financial
guidance for the full year 2023, anticipated future
orders, anticipated future operating and financial
performance, treatment results, therapy adoption, innovation, and
the performance of the MRIdian systems. Actual results could
differ from those projected in any forward-looking statements due
to numerous factors. Such factors include, among others, the
ability to commercialize the MRIdian Linac System, demand for
ViewRay's products, the ability to convert backlog into revenue,
the timing of delivery of ViewRay's products, the timing, length,
and severity of the COVID-19 pandemic, including its impacts across
our businesses on demand, our operations and global supply chains,
the results and other uncertainties associated with clinical
trials, the ability to raise the additional funding needed to
continue to pursue ViewRay's business and product development
plans, the inherent uncertainties associated with developing new
products or technologies, competition in the industry in which
ViewRay operates, and overall market conditions. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to ViewRay's business in
general, see ViewRay's current and future reports filed with the
Securities and Exchange Commission, including its Annual Report on
Form 10-K for the fiscal year ended December
31, 2022 and its Quarterly Reports on Form 10-Q, as updated
periodically with the Company's other filings with the SEC. These
forward-looking statements are made as of the date of this press
release, and ViewRay assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law.
View original
content:https://www.prnewswire.com/news-releases/siteman-cancer-center-at-washington-university-treats-2-000th-patient-with-mridian-mri-guided-radiation-therapy-301760219.html
SOURCE ViewRay, Inc.